NeuroBo Transforms into MetaVia Inc.

NeuroBo Pharmaceuticals, soon to be renamed MetaVia Inc., is realigning its corporate identity to focus on cardiometabolic disease therapies, with the transition effective November 29, 2024. Trading on Nasdaq under the new ticker MTVA, MetaVia aims to highlight its innovative pipeline, including:

1. DA-1241: A GPR119 agonist for metabolic dysfunction-associated steatohepatitis (MASH), with Phase 2a trial data expected in December 2024.
2. DA-1726: A dual OXM analog for obesity, with top-line Phase 1 MAD cohort results anticipated in Q1 2025.

MetaVia emphasizes its strong funding foundation and ambition to deliver next-generation treatments.